CIK 0001396814
- Large accelerated filer
Pacira BioSciences, Inc.
Sign in to watch- Ticker
- PCRX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 510619477
- Phone
- +1 650-242-8052
- Business address
- 2000 SIERRA POINT PARKWAY, SUITE 900, BRISBANE, CA, 94005
- Former names
- Pacira Pharmaceuticals, Inc., PACIRA INC, Blue Acquisition Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $217,920
- in 1 filing, $218K under 10b5-1 plans
Net −$217,920. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-17 | Froimson Mark Director | Other disposition | −20,136 | $36.50 | $735K | 6,405 |
| 2026-11-17 | Froimson Mark Director | Returned to the company | −6,405 | $36.50 | $234K | 0 |
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −4,693 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −8,437 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −8,027 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −7,626 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −8,225 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −12,925 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −11,279 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −10,891 | 0 | ||
| 2026-11-17 | Froimson Mark Director | Returned to the company · Stock Option (Right to Buy) | −8,144 | 0 | ||
| 2026-06-10 | Froimson Mark Director | Grant or award | +6,405 | 26,541 | ||
| 2026-06-10 | Froimson Mark Director | Grant or award · Stock Option (Right to Buy) | +10,891 | 10,891 | ||
| 2026-03-17 | Froimson Mark Director | Sale | −500 | $21.81 | $11K | 20,136 |
| 2025-06-11 | Froimson Mark Director | Grant or award | +6,163 | 20,636 | ||
| 2025-06-11 | Froimson Mark Director | Grant or award · Stock Option (Right to Buy) | +11,279 | 11,279 | ||
| 2024-08-12 | Froimson Mark Director | Purchase | +1,400 | $11.58 | $16K | 14,473 |
| 2024-06-12 | Froimson Mark Director | Grant or award | +5,230 | 13,073 | ||
| 2024-06-12 | Froimson Mark Director | Grant or award · Stock Option (Right to Buy) | +12,179 | 12,179 | ||
| 2023-06-14 | Froimson Mark Director | Grant or award | +1,775 | 7,843 |
Page 1 of 2 · 25 trades